GI SIDE EFFECTS
EVOTAZ DEMONSTRATED A LOW RATE OF GI SIDE EFFECTS1
Results from Study 114 in both arms through 144 weeks (Grades 2-4)
Nausea occurred in 2% of patients in both study arms; diarrhea occurred in 2% of patients in the EVOTAZ arm, and in 1% of those in the REYATAZ/r arm. All other treatment-emergent GI disorders Grades 2-4 (such as vomiting and upper abdominal pain) occurred in less than 2% in the EVOTAZ arm.